ClinicalTrials.gg
CompletedNCT04102943PK-TACTUpdated Apr 15, 2026

Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.

A Phase 4 interventional study of tacrolimus tablet and tacrolimus capsules in Kidney Transplant, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Nov 2017, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics and tolerability of Tacrolimus tablet(TacroBell) in kidney transplant recipients.

Read the detailed description

This study is a Single center, randomized, open-label, Phase IV study to evaluate the pharmacokinetics and tolerability of Tacrolimus tablet(TacroBell) administration for 24 Weeks in patients after renal transplantation.

02

Conditions studied

  • Kidney Transplant
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 19 years old(male or female)
  • Patients who are planning to receive a kidney from a deceased or a living non-related/related donor
  • Agreement with written

Exclusion criteria

Exclusion Criteria:

  • Previously received organs other than kidneys or who are planed to be transplanted simultaneously
  • Diagnosed with cancer in the last five years [Patients, however, who have recovered from skin cancer (squamous cell/basal cell carcinoma) or thyroid cancer can be enrolled.]
  • Patients or donors who have positive test result
  • Inadequate for registration under the judgment of the investigator due to severe gastrointestinal disorders
  • Severe systemic infection requiring treatment
  • Prior to the kidney transplantation

    • Treatment with active liver disease or Liver function test(T-, (AST), Alanine transaminase(ALT))is over 3 times than upper normal limit
    • White Blood Cell(WBC) \<2.5 x10\^3/μL, or \<75 x10\^3/μL
  • Pregnant women or nursing mothers
  • Fertile women who not practice with appropriate methods
  • Participated in other trial within 4 weeks
  • In investigator's judgment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Tacrolimus1

    Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.

    Drug: tacrolimus tablet

  • Active comparator
    Tacrolimus2

    Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.

    Drug: tacrolimus capsules

Interventions

  • * Orally, twice a day in the morning and night * After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.

    Also known as: tacrobell tablet

  • * Orally, twice a day in the morning and night * After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.

    Also known as: prograf capsules

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum concentration of drug in serum)

    Measurement of TDM of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours)

  2. AUCt (Area under the plasma concentration-time curve from time zero to time t)

    Measurement of TDM of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours)

Secondary outcomes

  1. Tmax (Time of peak concentration)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours)

  2. AUC∞ (Area under the plasma concentration-time curve from time zero to infinity)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours)

  3. Cmax (Maximum concentration of drug in serum)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  4. AUCt (Area under the plasma concentration-time curve from time zero to time t)

    Measurement of TDM of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  5. Tmax (Time of peak concentration)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  6. AUC∞ (Area under the plasma concentration-time curve from time zero to infinity)

    Measurement of TDM of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  7. Dose normalized Cmax(Maximum concentration of drug in serum)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours), At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  8. Dose normalized AUCt(Area under the plasma concentration-time curve from time zero to time t)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours), At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  9. Dose normalized Tmax(Time of peak concentration)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours), At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

  10. Dose normalized AUC∞(Area under the plasma concentration-time curve from time zero to infinity)

    Measurement of therapeutic drug concentration monitoring(TDM) of tacrolimus after administration of tacrolimus tablets or tacrolimus capsules

    Time frame: At 2weeks predose(0hour)and dose(0.5,1,1.5,2,3,4,8,12hours), At 24weeks predose(0hour)and dose(0.5,1,1.5,2,3,4hours)

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Sep 2020, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2019
First posted
Sep 25, 2019
StartActual
Nov 30, 2017
Primary completionActual
Sep 29, 2020
CompletionActual
Sep 29, 2020
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04102943
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Nov 30, 2017
Primary completion
Sep 29, 2020
Completion
Sep 29, 2020
Last update
Apr 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion